The Best Behavioral Health Outcome Tracking Platforms in 2026

Disclosure. Brand North is a marketing partner of ERP Health. We do not resell their platform, and we do not take a referral fee or commission on any subscription. The signup form below routes to Brand North’s team, who make the introduction directly — nothing here changes what we tell you about a competing product, and two of ERP Health’s real limitations are named plainly in the section below.

Outcome tracking in behavioral health is the standardized, repeated measurement of a patient’s clinical progress, using instruments such as the PHQ-9, GAD-7, or BAM. Outcome tracking exists because most treatment centers cannot produce a success number that survives scrutiny. A 2015 paper in Substance Abuse Treatment, Prevention, and Policy found that standardized tools for measuring addiction-treatment success “are not readily available in the US,” and that the definition of “success” in recovery is “at best, vaguely defined.”

The measurement gap is why regulators are paying attention. In June 2025, Evoke Wellness paid $1.9 million of a $7 million FTC penalty for deceptive outcomes marketing under the Opioid Addiction Recovery Fraud Prevention Act. Verified outcome data is the thing standing between a center’s marketing and that kind of exposure — not a nice-to-have.

1. ERP Health collects the widest verified instrument library reviewed here

ERP Health is a Philadelphia-based outcomes platform whose product, GRO, collects patient-reported measures across 26 standardized instruments — the widest verified library in this review — through three channels: an on-site device, remote links sent to patients, and structured alumni check-ins after discharge. The core four instruments (Holistic Hexagon, GAD-7, PSS, PHQ-9) run automatically on a recurring schedule; program-based instruments include BAM, ACE, AUDIT and Readiness to Change.

ERP Health has held NAATP Foundation for Recovery Science and Education (FoRSE) technology-partner status since December 2021, connecting subscriber data to the FoRSE Clinical Data Repository via API at no additional charge — the same registry that ran roughly 300,000 episodes of care across 136 providers in its 2025 annual summary. ERP Health is also a Qualified Service Organization under 42 CFR Part 2, the correct and specific designation for a vendor handling substance use disorder records.

Read “syndication” carefully before signing. ERP Health does not publish, benchmark, or make provider outcome data publicly visible anywhere this review located — no public provider profile, no comparative report, no directory listing. What a subscribing center receives is internal: clinical dashboards, and its own data to use in its own payer negotiations. The FoRSE connection is real and valuable, but it is not exclusive — Kipu, Sigmund, and BestNotes offer the identical no-cost API path to the same registry natively.

Two more facts worth your compliance officer’s attention. ERP Health does not publish SOC 2 or HITRUST certification, and this review found no peer-reviewed research or named customer case study anywhere on its site. Its Master Services Agreement also grants the company perpetual rights to retain de-identified data even after a customer terminates the contract — standard-looking language, and exactly the kind that gets skipped at signature and remembered at an audit.

None of that makes ERP Health a bad choice. The named gaps make it a real one: genuine instrument breadth, a genuine FoRSE connection, and genuine gaps that put it in the same position as most vendors here, not above them.

Brand North partners with ERP Health directly. Sign up with ERP Health through Brand North → — tell us about your program and we’ll make the introduction.

2. Vista Research Group publishes its actual post-discharge contact rate

Vista Research Group publishes the one number every other vendor in this category avoids: its actual post-discharge contact rate. Where most vendors imply near-total follow-up, Vista states 46% to 56% per survey wave, achieved with up to 15 contact attempts and a paid patient stipend, at 1, 6 and 12 months post-discharge. The published rate is the reason to include Vista even for a center that chooses someone else — the number is the honest ceiling to measure every other vendor’s implied claims against.

Vista’s instruments include PHQ-9, GAD-7, PCL-6 and C-SSRS, with a named Kipu integration that auto-imports completed surveys as PDFs into the patient chart. Pricing is published: $120 per patient for the full post-treatment follow-up cycle, capped by random sampling above 275 annual discharges — one of only two vendors in this cluster willing to state a real number without a sales call.

Vista publishes no position on 42 CFR Part 2, SOC 2 or HITRUST that this review located. Treat the contact-rate figure as honest, not great: under half of discharged patients, at best, are reachable at all — and the harder-to-locate half of any cohort tends to be the group doing worse, which tempers confidence in any success rate built from the group Vista does reach.

3. Greenspace Health sells the broadest EMR reach in the category

Greenspace Health sells the broadest EMR reach in the category, built for behavioral health generally rather than addiction treatment specifically. Greenspace claims 500+ evidence-based instruments (only PHQ-9 and GAD-7 are named individually) with configurable weekly-to-monthly collection, and states integration with more than 85 EHR/EMR systems.

Greenspace is the measurement layer inside Qualifacts’ Measurement-Based Care product, embedded into CareLogic since a May 2025 partnership, with InSync integration underway. A center running Qualifacts is probably already running Greenspace behind its outcomes module.

Its compliance posture is SOC 2 Type II and HIPAA; 42 CFR Part 2 and HITRUST are not claimed, and the “500+” instrument library is not itemized beyond the two named instruments — treat the count as a vendor claim, not a checkable fact.

4. NeuroFlow (formerly Owl) is the acquisition roll-up of this category

NeuroFlow is the acquisition roll-up of this category — Owl Insights was acquired in June 2024, following NeuroFlow’s 2023 acquisition of Capital Solution Design. The combined platform claims 400+ behavioral health assessments and 17 million lives under contract, figures from the acquisition announcement rather than an independent audit.

Owl’s technology was previously selected by Recovery Centers of America for outcomes measurement in 2021, giving NeuroFlow real deployment history in residential addiction treatment specifically. A vendor pitch or case study still saying “Owl” needs confirming for product and era before anyone relies on it.

5. Blueprint has repositioned outcome tracking inside a broader AI product

Blueprint has repositioned from a measurement-based-care platform into an AI assistant for outpatient therapists, with outcome tracking now one feature inside a broader product. Blueprint supports a validated instrument library including PHQ-9, GAD-7 and PCL-5, and publishes real per-session pricing — Core is free, Plus is $0.99 per session, Pro is $1.49.

The published Blueprint benchmarks are specific: an 11.8-point PHQ-9 reduction and a 9.3-point GAD-7 reduction over 12 weeks. Read those as vendor-derived from Blueprint’s own customer data, not peer-reviewed research. Blueprint is built for outpatient private practice, not residential addiction treatment, and states no position on alumni follow-up or 42 CFR Part 2.

Which EMRs include a native outcomes module?

Most EMRs claim an outcomes feature. Few name their instruments, and fewer still publish anything. The full CRM-versus-EMR distinction matters here too: an outcomes module bolted onto your existing EMR removes an integration project entirely, which is worth checking before buying a standalone platform.

The table below records, for the six EMRs covered in this cluster, whether a native outcomes module exists, which instruments each one names, whether alumni tracking ships with it, which accreditation standards each cites, and whether pricing is published.

EMR	Outcomes module	Instruments named	Alumni tracking	JC / CARF stated	Pricing
BestNotes	OutcomeTools, included free	~45, most specific set reviewed	No dedicated module	Both — cites CTS.03.01.09 by number	Published
Kipu	Outcomes Measurement / FIT	7: BAM, GAD-7, PHQ-9, AED V4, CEST, DASS-21, RAS	Yes, via Team Recovery (acquired April 2026)	Joint Commission only	Contact sales
Qualifacts	MBC, powered by Greenspace	11 native + Greenspace’s unnamed library	Not verified	Neither stated	Contact sales
Sunwave	None — Alumni Management only	None named	Yes, the strongest alumni module reviewed	Neither stated	Contact sales
Netsmart	None (CAMS-care partnership only)	2: CAMS Framework, SSF	Not verified	Neither stated	Contact sales
Alleva	None verified	None named on Alleva’s own site	Not verified	Neither stated	Contact sales

BestNotes stands out here for the same reason it stands out in our CRM review: it ties its outcomes practice to the actual accreditation standard, names its instruments individually, and includes the module at no extra cost. A center already running BestNotes, Kipu, Sunwave, or Alleva as its EMR — all covered in that review — checks the native module before shopping a standalone platform.

See the full EMR review for how these platforms compare on clinical charting, billing and compliance rather than outcomes alone.

Alumni tracking solves a different problem than outcome measurement

In-treatment outcome measurement asks how a patient is doing clinically. Alumni tracking asks whether you can find them at all, months after they’ve left. Four tools worth knowing, none a substitute for the six platforms above:

CHESS Health (eRecovery / Connections) has the strongest independent evidence of any tool in this category — a peer-reviewed RCT in JAMA Psychiatry (2014), n=349, 12-month follow-up, showing fewer risky drinking days and higher abstinence versus standard care. HITRUST r2 certified, integrates with Lightning Step.

WEconnect Health Management published a more recent result in JAMA Network Open (December 2024): app users had 35% fewer days of opioid use and stayed in treatment roughly 19% longer.

CaredFor (part of ContinuumCloud since January 2022) is deployed at scale — American Addiction Centers’ “AAC Together” launched on it in February 2026 — but does not name standardized instruments or publish response rates; it uses proprietary “Wellness Trackers” instead.

DynamiCare Health combines contingency-management incentives with substance testing and telehealth coaching, and received a $1.08 million NIH Phase II award in September 2024.

Does measurement-based care work?

Measurement-based care produces a small, genuine effect on symptom reduction, not the dramatic result any single vendor’s case study implies. SAMHSA’s ISMICC report defines it as a clinical process using standardized, repeated measurements to inform treatment jointly with the patient — and concedes the field has no consensus definition beyond that.

The strongest positive trial, a 2015 American Journal of Psychiatry study, found 73.8% remission versus 28.8% for standard care in major depression. The trial used a protocolized medication algorithm at a single site and is not an addiction-treatment trial, though it is cited far more broadly than its scope supports. The honest average, from a 2021 meta-analysis of 58 studies and 21,699 patients, is a small effect (d = 0.15). A 2016 Cochrane review of 17 trials and 8,787 participants found insufficient evidence that routine outcome monitoring improves outcomes at all, citing high risk of bias across the trial base.

Specifically for addiction treatment, a 2022 review found only two published randomized controlled trials support wider measurement-based care implementation in substance use settings. Adoption sits under 20% of behavioral health practitioners industry-wide, per a 2019 review — either the market opportunity or the implementation risk, depending on how your clinical team receives a new measurement requirement. SAMHSA’s own guidance adds one governance note worth repeating before rollout: outcome data belongs outside any evaluation of individual providers’ performance, because clinicians who sense it as surveillance disengage from it.

What percentage of discharged patients can a center reach?

Well-funded academic studies with dedicated staff trackers reach 70 to 89 percent follow-up; commercial platforms without that resourcing reach far less. NIDA-funded investigators average 84% follow-up, with a documented range as wide as 36–100%. Vista’s published 46–56% is the realistic commercial figure without a dedicated tracking staff.

Real-world engagement is lower still. A 2025 scoping review found substance-use treatment engagement rates as low as 1.5% to 2.4% in one Medicare Advantage study, and initiation rates in the 27–33% range across multiple health-system studies. The chart below places every figure side by side.

The gap matters for a reason beyond honesty: the patients a center can’t locate for follow-up are, on average, the ones doing worse. Every unadjusted “success rate” is biased upward by the people missing from it.

Why do so few vendors publish their real numbers?

Most treatment-outcome vendors sell through a sales process priced by census and module mix, which is also why so few publish their instrument libraries in full. The chart below counts only instruments each vendor names individually on its own site — Greenspace Health and NeuroFlow claim larger libraries (500+ and 400+ respectively) without itemizing them, so they are excluded rather than plotted on an unverifiable number.

BestNotes and ERP Health are the only two vendors reviewed here whose instrument claims survive a direct count against their own published documentation.

Why does self-reported outcome data keep drawing regulatory scrutiny?

Self-reported outcome data draws regulatory scrutiny because success rates without independent verification have repeatedly become the specific claim that attracts journalism and enforcement action in this industry. STAT News and the Boston Globe, in a widely-cited 2017 investigation, reported that Recovery Centers of America cited internal data claiming 70% of patients were still off drugs one month after discharge — self-reported, no published methodology, alongside documented care deficiencies at the same facilities.

A 2021 Health Affairs secret-shopper audit of 613 residential programs found a third of callers were offered admission before any clinical evaluation, common “even among programs with third-party accreditation and state licenses.” Accreditation does not predict ethical intake practice, which is the strongest argument that verified, third-party-visible outcome data is the real differentiator — not another credential on a wall. The FTC’s $7 million action against Evoke Wellness in June 2025, cited at the top of this article, is the current version of that same enforcement pattern.

How do you choose among these outcome platforms?

Choosing among these outcome platforms starts with your EMR. BestNotes, Kipu, Sunwave, or Alleva already running your clinical record makes the native outcomes module the first check — covered in the CRM review — before buying a standalone platform. The widest instrument coverage and a free FoRSE registry connection point to ERP Health; read the data-retention clause first, the same way any vendor contract gets read. The most honest number to hold every other vendor’s claims against is Vista’s published contact rate, worth reading before anyone’s dashboard.

The number that matters is not the count of completed assessments. The number that matters is the share of discharged patients a center reaches, how that share compares to the honest ceiling above, and whether the resulting figure survives being read back to a family considering the program. See cost per admit for the marketing-side half of this same discipline: verified numbers, or no numbers at all.